$CRDL

Five biotech companies reached 52-week highs on August 26, 2026. Cardiol Therapeutics (CRDL) rose 7% to $2.27, reporting a narrower Q2 loss. NeoGenomics (NEO) hit $17.46 after securing Medicare/Medicaid coverage for its RaDaR ST test and reported a Q2 profit. Seaport Therapeutics (SPTX) surged 12% to $28.37 post-IPO, with a wider Q2 loss. Rapport Therapeutics (RAPP) gained 2% to $52.83, advancing its CNS drug candidates. Cullinan Therapeutics (CGEM) reached $23.19, with a narrower Q2 loss and FD

Summit Therapeutics (SMMT) +7% on positive Phase III trial data; Celularity (CELU) +15% despite Nasdaq compliance issue; Biodesix (BDSX) +8% on Q2 revenue growth; Cardiol Therapeutics (CRDL) +12% with narrowed Q2 loss; Edesa Biotech (EDSA) +11% after public offering announcement.

Several biotech stocks hit 52-week highs on August 25, 2026. Generate Biomedicines (GENB) rose 15% to $22.67, despite a wider net loss. Biodesix (BDSX) climbed 10% to $30, reporting a 34% revenue increase. CareDx (CDNA) gained 6%, with Medicare coverage for its transplant tests. Cumberland Pharmaceuticals (CPIX) rose 10% to $8.70, advancing Ifetroban in trials. Cardiol Therapeutics (CRDL) increased 7% to $2.02, with CardiolRx in Phase 3 trials.

Andrew Peller (ADW.A) reached a 52-week high of $8.00 after completing a transaction with Fairfax. Algoma Central (ALC.TO) hit $25.25, reporting Q2 revenues of $258,273. Argo Graphene (C.ARGO) hit $1.15 after appointing a new CEO. Boralex (BLX) reached $37.24 following its acquisition by Brookfield. Bank of Montreal (BMO) hit $258.11 after selling Moneris. Other companies also hit 52-week highs with varying news.

The article compares small-cap medical stocks Aptorum Group (NASDAQ:APM) and Cardiol Therapeutics (NASDAQ:CRDL). It cites beta values of 0.3 for APM and 0.77 for CRDL, institutional ownership of 3.8% vs 12.5%, and insider ownership of 64.0% vs 5.3%. MarketBeat data shows CRDL consensus target price of $8.50 (upside 553.85%). It also states APM has higher revenue and earnings.

Cardiol Therapeutics Inc. announced the results of its 2025 Annual General Meeting of Shareholders, where all Management resolutions were approved. Dr. Timothy Garnett was elected to the Board of Directors, bringing extensive drug development and commercial expertise to the company. The company also provided updates on its clinical trials for CardiolRx™ in recurrent pericarditis and acute myocarditis, and the development of CRD-38 for heart failure.

Innovation is at its peak in the Zacks Medical-Drugs industry. AKBA, IRWD, PYXS, CRDL and PSTV may prove to be good additions to one's portfolio.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.